



HHS Public Access

Author manuscript

Curr Treat Options Infect Dis. Author manuscript; available in PMC 2016 June 01.

Published in final edited form as:

Curr Treat Options Infect Dis. 2015 June ; 7(2): 101–112. doi:10.1007/s40506-015-0046-4.

Clinical Treatment Options Infectious Diseases: Update on PrEP Implementation, Adherence, and Advances in Delivery

Susanne Doblecki-Lewis, MD¹, Stephanie Cohen, MD, MPH^{2,4}, and Albert Liu, MD, MPH^{3,4}

¹Division of Infectious Diseases, University of Miami Miller School of Medicine, San Francisco

²Population Health Division, San Francisco Department of Health, San Francisco

³Bridge HIV, San Francisco Department of Health, San Francisco

⁴Division of Infectious Diseases, University of California, San Francisco

Opinion Statement

Pre-exposure prophylaxis (PrEP) is an effective and evidence-based HIV-prevention option and is recommended for individuals with substantial risk for HIV infection [1]. Randomized controlled trials have demonstrated that daily oral PrEP dramatically reduces the risk of HIV infection when it is taken as directed. Concerns regarding widespread emergence of antiretroviral resistance attributable to PrEP and behavioral disinhibition have to date not been observed in clinical trials and open-label demonstration projects. PrEP has great potential as part of an HIV risk reduction strategy and barriers to wider implementation including community education, prescriber availability, and elimination of financial barriers should be aggressively pursued. Adherence is critical to PrEP efficacy and has varied across study populations; developing and refining ways of measuring and supporting adherence is essential to the success of PrEP. Evaluation of long-acting medications and alternative formulations for PrEP is underway and may lead to the wider implementation and impact of PrEP.

Keywords

HIV Prevention; Pre-exposure prophylaxis; antiretrovirals

Introduction

Pre-exposure prophylaxis (PrEP) is an HIV prevention strategy involving use of antiretroviral medications for HIV-uninfected individuals who are at risk for HIV

Contact for Correspondence: Albert Liu, MD, MPH Director, HIV Prevention intervention Studies Bridge HIV | San Francisco Department of Public Health 25 Van Ness Avenue, Suite 100, San Francisco, CA 94102 P: 415-437-7408 | F: 415-431-7029 albert.liu@sfdph.org.

Compliance with Ethics Guidelines

Conflict of Interest

Albert Liu donated a study drug to the US PrEP demo project, of which Liu is the protocol chair. Susanne Doblecki-Lewis has no conflicts of interest. Stephanie Cohen reports that Gilead donated a study drug to the US PrEP demo project, of which Cohen is the site co-PI.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by the author.

acquisition initiated before exposure. PrEP effectiveness has been established through large randomized controlled trials of daily oral medication for sexually active men who have sex with men (MSM) as well as heterosexual men and women, and intravenous drug users demonstrating risk reductions of 44-75% compared with placebo [2-5]. The United States Food and Drug Administration subsequently approved daily oral fixed-dose combination tenofovir-emtricitabine (TDF/FTC, marketed as Truvada) for HIV prevention, and the Centers for Disease Control and Prevention released comprehensive guidelines for PrEP prescribing in May 2014[1, 6].

PrEP demonstrates great promise as a component of combination prevention strategies. Data continue to emerge reinforcing the safety and efficacy of the intervention, and details regarding behavioral changes, adherence, optimal counseling strategies and follow-up are now becoming available. Questions regarding the optimal implementation strategy for this intervention remain, with numerous PrEP demonstration projects currently underway to attempt to clarify the location, personnel, and resources required for PrEP provision. Additionally, clinical trials are underway to assess different medications, dosing strategies and delivery mechanisms for PrEP that may alter the landscape for biomedical prevention in the near future. In this review we will summarize emerging literature relevant to PrEP implementation including adherence, risk compensation, uptake and delivery, and strategies for long-acting or intermittent dosing of PrEP medication that are currently under investigation.

Antiretroviral Medication for PrEP

The scientific basis for antiretroviral use for prevention initiated prior to sexual exposure arises from non-human primate studies in which tenofovir and emtricitabine, two drugs with favorable pharmacokinetics in rectal and vaginal mucosa, reduced infection risk in macaques by 70-100% when administered prior to mucosal SIV exposure [7-11]. Initial large clinical trials therefore generally assessed TDF, with or without combination FTC. These randomized controlled clinical trials in humans have provided evidence that daily antiretroviral-based oral PrEP, as part of a comprehensive prevention strategy, is safe and effective for MSM and heterosexual men and women as well as intravenous drug users at risk for HIV infection [2-5]. Both TDF and TDF/FTC regimens have been shown to be effective when used, with somewhat higher (but not statistically significant) protection with TDF/FTC observed in the Partners PrEP trial [12], however TDF/FTC is the only regimen currently approved by the United States Food and Drug Administration for HIV pre-exposure prophylaxis [6].

Side Effects and Monitoring

Combination TDF/FTC is well tolerated. The most common side effects are mild gastrointestinal complaints occurring in the first 1-2 weeks of beginning medication and usually improving after this point [2, 4-6]. Renal tubular effects of TDF have been observed in large trials of HIV-positive individuals receiving this medication for treatment of infection [13, 14], but only a mild decline in creatinine clearance has been observed in studies using this medication for PrEP and this effect reverses upon discontinuation of the drug [15]. TDF/FTC PrEP is not recommended for individuals with a baseline creatinine

clearance of less than 60 mg/dL, and baseline and interval renal function monitoring is advised for all patients receiving this medication for PrEP [1]. A small, but statistically significant decrease in bone mineral density is also observed in the first 24-36 weeks after starting PrEP [4, 16, 17] the clinical importance of this decrease is unclear, as no excess fractures have been observed in the PrEP treatment arm of the completed randomized controlled studies [4, 16].

Despite the well-established safety profile of TDF/FTC, concern regarding side effects is a common reason for declining to initiate or electively discontinuing PrEP [18, 19] and a common concern on the part of providers who are hesitant about PrEP prescribing [20, 21]. Careful assessment of putative side effects and counseling and support regarding these events is important to avoid unnecessary PrEP discontinuation among individuals who remain at risk for HIV infection.

Resistance

Unrecognized early/acute HIV infection at the initiation of PrEP accounts for the vast majority of cases of drug resistance identified in clinical trials to date (Table 1)[2, 4, 5, 22]. Adequate clinical and laboratory screening for early HIV infection at the time of PrEP initiation is essential to avoid resistance and to initiate effective combination antiretroviral therapy for treatment of infection [1]. Resistance to drug emerging after PrEP has been established is much less common, likely because most infections occur in the absence of detectable drug levels to drive resistance. PrEP-related mutations were detected with ultra-deep sequencing in 4 of 51 active-arm seroconverters infected after enrollment in the Partners PrEP study, 2 of which had detectable drug levels after HIV acquisition and mutations associated with the drugs they were assigned. Overall, detectable drug levels were predictive of identification of resistance [23]. Among 48 iPrEx active-arm participants with incident infections, none had clinically detectable resistance, and only 2 had minor variant resistance to FTC at <1% frequency [22]. In the Fem-PrEP study, FTC resistance was detected by clinical assays in 4 seroconverters in the active arm of the study, with an additional case of minor variant resistance to FTC identified using more sensitive sequencing techniques; these rates of resistance are thought to be similar to those found among transmitted infections in the geographical area of the study [24]. Modeling studies suggest that PrEP is unlikely to contribute substantially to prevalence of drug-resistant virus in the community in comparison to resistance developed during treatment of chronic HIV infection [25].

Risk Compensation

Substantial behavioral changes while receiving PrEP (risk compensation or risk disinhibition) have not been observed in the randomized controlled trials to date [2, 4, 5, 18, 26]. Number of partners and episodes of condomless sex decreased during the course of the iPrEx study and the open-label extension (iPrEx OLE) of this study [4, 24, 27]. An analysis of sexual behavior of participants in the Partners PrEP study likewise did not find evidence for increases in condomless sex during the blinded study or after release of results [26]. All PrEP clinical trials are conducted with dedicated risk reduction counseling as well as provision of condoms and comprehensive sexual health care; adaptation of these

comprehensive prevention services may be challenging in some non-research implementation sites. In one survey of potential PrEP recipients, 35% of young MSM indicated intent to decrease condom use with PrEP [28], but such dramatic increases have not been observed in any PrEP setting to date. Making PrEP available could facilitate engagement of individuals at risk for HIV and uptake of other prevention practices (prevention synergy), including frequent HIV testing, provision of condoms, long-term counseling regarding status disclosure and condom use, and treatment of sexually transmitted infections [18, 29]. As risk behavior in placebo-controlled trials may not reflect sexual practices in more real-world settings, evaluation of sexual behavior in open-label PrEP programs is being planned in a number of PrEP demonstration projects.

Adherence

PrEP effectiveness is directly related to medication adherence. In the iPrEx study of PrEP for MSM and transgender women, only 9% of individuals seroconverting during the study had detectable (any) drug levels at the visit, compared with 51% of HIV-negative controls [4]. Although overall PrEP efficacy was 44% in the study, among participants with drug detectable drug levels, PrEP efficacy was estimated to be more than 90% [4, 30]. The Partners PrEP study, evaluating PrEP among discordant couples, demonstrated 67-75% protective efficacy overall and also reported high levels of drug detection [2]. The VOICE and FemPrEP trials, both large trials of PrEP for heterosexual women, failed to show PrEP effectiveness [31, 32]. Analysis of serum drug levels from the VOICE trial demonstrated detectable drug in fewer than 23% of women in the active arm of the study. In contrast, self-reported adherence was 80-90% [31]. Extrapolating from clinical trial data and controlled pharmacokinetic studies, an estimate of protective effect with various levels of adherence may be formulated. Analysis of TDF and FTC drug levels from the iPrEx and STRAND studies approximated 76% protection for 2 doses of oral TDF/FTC weekly, 96% for 4 doses weekly, and 99% for 7 doses weekly [33]. In the open-label extension of iPrEx, no participants became infected with drug levels consistent with taking doses/week. These data suggest that less than daily dosing may provide some protection against infection, although daily dosing may help facilitate adherence through building a pill-taking routine and also afford some forgiveness for missed pills [18] and currently oral PrEP with TDF/FTC is only recommended for daily use.

Due to the inconsistent relationship between self-reported adherence and objective measures such as drug levels, most PrEP research studies include multiple adherence parameters: self report, pill counts, and plasma, peripheral blood mononuclear cell (PBMC) levels, hair, and/or dried blood spot (DBS) drug levels have been commonly measured. Plasma levels provide the ability to estimate short-term (2-7 days) adherence, while PBMCs provide information on medium-term (7-14 days) adherence [34-36] Drug levels in DBS and hair reflect longer term exposure to TDF/FTC and may be more feasible to collect and process in real-world settings [37].

Adherence in the clinical setting, when patients are aware that they are receiving an active medication that is proven to be effective when taken, may well be different from adherence in a clinical trial setting when benefit is unknown [38]. PrEP demonstration projects and

extensions of previous trials, in which participants are provided PrEP in an open-label fashion, are beginning to provide some data regarding longitudinal adherence in these settings. Recently reported data from the iPrEx open-label extension provides evidence that adherence is complex, with the most common pattern being initial adherence followed by discontinuation rather than intermittent use, and that while adherence is higher among those with highest sexual risk for infection, those discontinuing did also have ongoing behavioral risk for infection [18, 38].

As therapeutic drug monitoring is not currently recommended or practiced as part of routine PrEP prescribing, adherence to PrEP in real-world settings can be challenging to assess or estimate. Maintaining a neutral approach to questioning regarding adherence may help to reduce inflated adherence estimates due to desire to please or to avoid extended counseling, and may then allow discussion regarding new approaches that may improve adherence [38, 39].

Supporting PrEP Adherence

As adherence is crucial to PrEP effectiveness in the clinical setting, discussion regarding planned strategies for optimizing adherence is an important part of initial and follow-up counseling when initiating PrEP. In a qualitative study of the iPrEx participants, coordinating timing of medication dosing with another daily routine was helpful to adherence [40]. Ready access to medication in a keychain or other portable holder also facilitated adherence for some participants. Disruption in routine and not having medication available are consistently identified barriers to adherence [29, 40-42]. Technological support for PrEP adherence, such as text, email, and SMS messaging to remind or provide support for individuals receiving PrEP are also currently under investigation as tools to encourage adherence [43].

PrEP studies conducted with discordant couples have demonstrated the highest levels of adherence, emphasizing the importance of partner support in supporting adherence [41, 44]. High levels of adherence and efficacy in the Partners PrEP study may be partially explained by inclusion of stable discordant couples, for whom PrEP provides a relief from the “discordance dilemma” and who also provided substantial support for PrEP-taking [44]. In a Partners PrEP sub-study focused on adherence, some decline in adherence over time was observed [45]. Additionally, adherence <80% was more likely in younger participants, those with less sexual activity, and those with frequent alcohol use [45]. In the Fem-PrEP study effectiveness was impacted by low adherence [32, 41]. Analysis of adherence factors indicated that risk perception impacted adherence, with motivation increased for those with higher risk perception [46]. Community perception of PrEP, stigma associated with taking antiretroviral medications, and partner support (or lack of support) also impacted adherence across studies, emphasizing the need to consider not only individual-level but also partner and community factors [19, 41, 46-48].

PrEP implementation: opportunities and challenges

Several PrEP demonstration projects and implementation programs are underway to evaluate the uptake, adherence, sexual behaviors, safety and/or effectiveness of PrEP when

delivered in more real-world contexts. In the open-label extension (OLE) of the iPrEx trial, approximately three-quarters of HIV-negative participants who returned for study participation elected to take PrEP, with higher uptake among those reporting condomless receptive anal sex and having evidence of prior herpes infection [18] HIV incidence was lower among those receiving PrEP vs. those who chose not to receive PrEP (1.8 vs. 2.6/100 person years), and higher PrEP drug concentrations were associated with higher levels of protection [18]. An interim analysis of the open-label PROUD study in the United Kingdom which involved randomization to either immediate or delayed initiation of PrEP found that PrEP was highly protective in those receiving PrEP, and it was recommended that PrEP be offered to all study participants immediately [49].

While studies tracking pharmacy claims suggest that few patients in the US are being prescribed PrEP [50, 51], interest and uptake of PrEP among individuals with behavioral risk for HIV is high when offered as part of demonstration projects and without charge [18, 52]. In the US Demo Project evaluating PrEP delivery in STD clinics and a community health center, almost half of eligible referred clients, many of whom had not heard of PrEP and 87% of those who were self-referred to the project elected to take PrEP [52, 53].

As PrEP requires a prescription and safety monitoring by medical practitioners, healthcare providers play a critical role in successful PrEP implementation. Several studies among US providers found knowledge and support of PrEP to be high, particularly among HIV specialists, but prescribing of PrEP to be quite low across clinical groups [20, 21, 54-56]. Concerns expressed by providers include safety, efficacy, adherence, antiretroviral resistance, behavioral disinhibition, cost, and operational challenges of delivering PrEP in busy clinical settings [54-56]. Despite CDC guidance on PrEP, there are significant differences in the real-world practice of PrEP, including deciding who is eligible for PrEP, how persons are followed up, and how PrEP is discontinued [21]. Recently, a national clinician consultation PrEPline (855-448-7737) has been established to provide support to clinicians prescribing PrEP [57] and numerous groups are developing resources for clinicians to address barriers in scaling up PrEP delivery, including clinical practice guidelines [1] and tools to provide education around PrEP to patients [58], facilitate taking a sexual history [59], identify appropriate PrEP candidates [60], and prescribe and monitor PrEP safely [61]. Cost of medication is a real or perceived barrier to starting PrEP in many settings [55, 62]; commercial insurance frequently covers PrEP medication but may involve high copayments [63, 64]. Pharmaceutical patient assistance programs, Medicaid, and some specialized governmental assistance programs are available to assist with payment for PrEP in the United States [65, 66]. HIV infection disproportionately affects historically stigmatized groups as well as populations with lower socioeconomic status and decreased access to medical care [67-69]; engaging people who are at risk for HIV with appropriate and accessible information regarding PrEP as a prevention option, enabling access to PrEP providers, and removing economic barriers to biomedical prevention methods are necessary to ensure that PrEP implementation occurs in an equitable manner that minimizes disparities and maximizes impact [70].

Alternative Dosing Strategies for PrEP

While the first generation of PrEP trials evaluated daily oral dosing of TDF/FTC, PrEP strategies that involve intermittent or on-demand dosing of oral PrEP medication are currently under investigation. The IPERGAY study for MSM in France and Canada involves taking two doses of medication in the 24 hours prior to anticipated sex and one each in the 2 days following sex; this strategy produces blood levels thought to be protective and was stopped early due to a significant reduction in infection in the study arm compared with placebo [71]. Preliminary adherence data indicate drug detection levels of 82-86% in the active arm [72] and additional data will be forthcoming. The UVRI Uganda Research Unit Study compared acceptability and adherence to daily and intermittent PrEP for discordant heterosexual couples, with intermittent dosing involving twice weekly dosing with an additional post-coital dose. More than 90% adherence to fixed doses was reported by bottle monitoring device, but only 45% adherence to post-coital dosing [73]. In a placebo controlled study comparing daily oral PrEP to fixed intermittent plus post-coital dosing for MSM and female sex workers in Kenya, a similar pattern was seen with 83% median adherence to daily dosing by MEMS cap monitoring versus 55% for fixed intermittent doses and 26% for post-coital doses. However, MEMS cap monitoring may have under-estimated intermittent and post-coital doses due to the practice of removing doses for post-coital dosing away from home, and difficulty with accurate recording of sexual activity [74]. Other studies, such as the U.S. HPTN 067/ADAPT to evaluate the feasibility of intermittent and on-demand oral PrEP are also underway.

Innovation in Drug Delivery and Long-Acting Medication

Antiretroviral compounds and formulations allowing less frequent dosing are in development and may have the potential to positively impact adherence and acceptability of PrEP. The paradigm of long-acting injectable prophylaxis that is acceptable and effective has been established with progestogenic contraception [75]. An international survey of potential PrEP users and a survey of young MSM in New York City indicated that long-acting injectable formulations were acceptable and preferred over oral daily PrEP by up to 80% of those surveyed [76, 77], while a similar survey in a cohort of Thai MSM indicated that daily oral PrEP was preferred over injectable forms [78].

GSK744, an injectable long-acting integrase inhibitor with the possibility of dosing every 3 months demonstrated efficacy in prevention of rectal and vaginal SIV infection in macaques and a phase IIa trial evaluating tolerability and acceptability of this compound for HIV negative men is underway [79, 80]. TMC278-LA, a long-acting injectable form of the non-nucleotide reverse transcriptase inhibitor (NNRTI) rilpivirine with potential for use as PrEP, has also completed phase I trials and a phase II trial in HIV-uninfected women is planned [80-82]. Additionally, dapivirine and maraviroc containing vaginal rings remaining in place for 28 days have demonstrated safety and acceptability in phase I human trials and a dapivirine ring is currently under evaluation in human efficacy studies [83]. These products and other long-acting agents have the potential to impact adherence and offer many potential advantages over oral medication requiring daily dosing. Challenges with long-acting injectable agents include injection site reactions, follow-up for HIV testing and re-dosing of medication, and theoretical concerns that individuals stopping injections will experience

prolonged suboptimal levels of medication that may lead to a greater risk of resistance will require investigation as these promising technologies become available [84].

Conclusion

PrEP is rapidly emerging as an important part of comprehensive HIV prevention programs, and has potential to impact HIV incidence. Consistently, adherence to medication is evident as the most important factor in realizing the benefits of PrEP [38, 42]. As PrEP moves toward wider implementation, improvements in understanding of adherence factors, and innovation in PrEP outreach to improve uptake and availability for all groups at risk for HIV infection will be required to decrease disparities in PrEP uptake and to maximize impact of this intervention.

References

- Centers for Disease Control and Prevention. Pre-Exposure Prophylaxis for the Prevention of HIV in the United States - 2014 Clinical Practice Guideline. 2014.
- 2**. Baeten JM, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. *N Engl J Med.* 2012; 367(5):399–410. [PubMed: 22784037] [The Partners-PrEP study was one of the first large studies of heterosexual discordant couples indicating significant risk reduction with daily oral TDF or TDF/FTC PrEP. Substudies and open-label continuation phase from this study continue to contribute information regarding durability of effect and factors related to adherence.]
- 3**. Choopanya K, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. *Lancet.* 2013; 381(9883):2083–90. [PubMed: 23769234] [This is the largest controlled trial demonstrating the efficacy and feasibility of oral PrEP for IDU in Thailand.]
- 4**. Grant RM, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. *N Engl J Med.* 2010; 363(27):2587–99. [PubMed: 21091279] [The iPrEX study was the first large placebo controlled trial to demonstrate risk reductions with PrEP and was conducted in MSM and TGW. Substudies have contributed substantially to information regarding correlates between adherence and protection in this population.]
- 5*. Thigpen MC, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. *N Engl J Med.* 2012; 367(5):423–34. [PubMed: 22784038] [The CDC TDF-2 study contributed to available data regarding efficacy of PrEP for prevention of heterosexual HIV transmission.]
- 6**. Food and Drug Administration. Truvada approved to reduce the risk of sexually transmitted HIV in people who are not infected with the virus. 2012. [These comprehensive clinical guidelines provide substantial information regarding screening patients for appropriateness of PrEP, laboratory testing, counseling, and follow-up for PrEP prescribers.]
7. Tsai CC, et al. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. *Science.* 1995; 270(5239):1197–9. [PubMed: 7502044]
8. Garcia-Lerma JG, et al. Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. *PLoS Med.* 2008; 5(2):e28. [PubMed: 18254653]
9. Parikh UM, et al. Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine. *J Virol.* 2009; 83(20):10358–65. [PubMed: 19656878]
10. Garcia-Lerma JG, et al. Intermittent prophylaxis with oral truvada protects macaques from rectal SHIV infection. *Sci Transl Med.* 2010; 2(14):14ra4.

11. Subbarao S, et al. Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges. *J Infect Dis.* 2006; 194(7):904–11. [PubMed: 16960777]
12. Baeten JM, et al. Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial. *Lancet Infect Dis.* 2014; 14(11):1055–64. [PubMed: 25300863]
13. Izzedine H, Harris M, Perazella MA. The nephrotoxic effects of HAART. *Nat Rev Nephrol.* 2009; 5(10):563–73. [PubMed: 19776778]
14. Young B, et al. Renal function in Tenofovir-exposed and Tenofovir-unexposed patients receiving highly active antiretroviral therapy in the HIV Outpatient Study. *J Int Assoc Physicians AIDS Care (Chic).* 2007; 6(3):178–87. [PubMed: 17579126]
15. Solomon MM, et al. Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis. *AIDS.* 2014; 28(6):851–9. [PubMed: 24499951]
16. Liu AY, et al. Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco. *PLoS One.* 2011; 6(8):e23688. [PubMed: 21897852]
17. Kasonde M, et al. Bone mineral density changes among HIV-uninfected young adults in a randomised trial of pre-exposure prophylaxis with tenofovir emtricitabine or placebo in Botswana. *PLoS One.* 2014; 9(3):e90111. [PubMed: 24625530]
- 18*. Grant RM, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. *Lancet Infect Dis.* 2014; 14(9): 820–9. [PubMed: 25065857] [This cohort provides important data regarding longitudinal follow-up of individuals receiving PrEP in an open-label study and indicates continued protection from HIV and lack of substantial behavior changes in those receiving PrEP.]
19. Liu A, et al. Early experiences implementing pre-exposure prophylaxis (PrEP) for HIV prevention in San Francisco. *PLoS Med.* 2014; 11(3):e1001613. [PubMed: 24595035]
20. Arnold EA, et al. A qualitative study of provider thoughts on implementing pre-exposure prophylaxis (PrEP) in clinical settings to prevent HIV infection. *PLoS One.* 2012; 7(7):e40603. [PubMed: 22792384]
21. Karris MY, et al. Are we prepped for preexposure prophylaxis (PrEP)? Provider opinions on the real-world use of PrEP in the United States and Canada. *Clin Infect Dis.* 2014; 58(5):704–12. [PubMed: 24319083]
22. Liegler T, et al. HIV-1 drug resistance in the iPrEx preexposure prophylaxis trial. *J Infect Dis.* 2014; 210(8):1217–27. [PubMed: 24740633]
23. Lehman DA, et al. Risk of Drug Resistance Among Persons Acquiring HIV Within a Randomized Clinical Trial of Single- or Dual-Agent Preexposure Prophylaxis. *Journal of Infectious Diseases.* 2015
24. Grant RM, et al. Drug resistance and plasma viral RNA level after ineffective use of oral pre-exposure prophylaxis in women. *AIDS.* 2014
25. Parikh UM, Mellors JW. HIV-1 drug resistance resulting from antiretroviral therapy far exceeds that from pre-exposure prophylaxis. *Clin Infect Dis.* 2012; 55(2):303–4. author reply 304. [PubMed: 22491333]
26. Mugwanya KK, et al. Sexual behaviour of heterosexual men and women receiving antiretroviral pre-exposure prophylaxis for HIV prevention: a longitudinal analysis. *Lancet Infect Dis.* 2013; 13(12):1021–8. [PubMed: 24139639]
27. Marcus JL, et al. No evidence of sexual risk compensation in the iPrEx trial of daily oral HIV preexposure prophylaxis. *PLoS One.* 2013; 8(12):e81997. [PubMed: 24367497]
28. Golub SA, et al. Preexposure prophylaxis and predicted condom use among high-risk men who have sex with men. *J Acquir Immune Defic Syndr.* 2010; 54(5):548–55. [PubMed: 20512046]
29. Amico KR, Stirratt MJ. Adherence to preexposure prophylaxis: current, emerging, and anticipated bases of evidence. *Clin Infect Dis.* 2014; 59(Suppl 1):S55–60. [PubMed: 24926036]

30. Dai JY, et al. Estimating the efficacy of preexposure prophylaxis for HIV prevention among participants with a threshold level of drug concentration. *Am J Epidemiol.* 2013; 177(3):256–63. [PubMed: 23302152]
31. Marrazzo, J.; R.G.; Nair, G., et al. Pre-exposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir/emtricitabine or vaginal tenofovir gel in the VOICE study (MTN 003).. 20th Conference on Retroviruses and Opportunistic Infections; Atlanta, GA. 2013;
- 32*. Van Damme L, et al. Preexposure prophylaxis for HIV infection among African women. *N Engl J Med.* 2012; 367(5):411–22. [PubMed: 22784040] [The FEM-PrEP study, together with the VOICE study (see #28, above) provide information regarding the importance of adherence to efficacy of PrEP; both failed to demonstrate risk reduction in the active arms, with low adherence across intervention arms.]
- 33*. Anderson PL, et al. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. *Sci Transl Med.* 2012; 4(151):151ra125. [This study used pharmacokinetic data from the STRAND study as well as clinical and drug level information from iPrEX to estimate protection from HIV with various levels of adherence.]
34. Castillo-Mancilla JR, et al. Tenofovir Diphosphate in Dried Blood Spots As an Objective Measure of Adherence in HIV-Infected Women. *AIDS Res Hum Retroviruses.* 2014
35. Castillo-Mancilla JR, et al. Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure. *AIDS Res Hum Retroviruses.* 2013; 29(2):384–90. [PubMed: 22935078]
36. Zheng JH, et al. Quantitation of tenofovir and emtricitabine in dried blood spots (DBS) with LC-MS/MS. *J Pharm Biomed Anal.* 2014; 88:144–51. [PubMed: 24055850]
37. Liu AY, et al. Strong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP). *PLoS One.* 2014; 9(1):e83736. [PubMed: 24421901]
- 38*. Amico KR. Adherence to preexposure chemoprophylaxis: the behavioral bridge from efficacy to effectiveness. *Curr Opin HIV AIDS.* 2012; 7(6):542–8. [PubMed: 22964887] [This review addresses adherence measures, known adherence factors, and suggested interventions to support adherence.]
39. Amico KR, et al. Supporting study product use and accuracy in self-report in the iPrEx study: next step counseling and neutral assessment. *AIDS Behav.* 2012; 16(5):1243–59. [PubMed: 22460228]
40. Gilmore HJ, et al. Participant experiences and facilitators and barriers to pill use among men who have sex with men in the iPrEx pre-exposure prophylaxis trial in San Francisco. *AIDS Patient Care STDS.* 2013; 27(10):560–6. [PubMed: 24093809]
41. Corneli AL, et al. FEM-PrEP: adherence patterns and factors associated with adherence to a daily oral study product for pre-exposure prophylaxis. *J Acquir Immune Defic Syndr.* 2014; 66(3):324–31. [PubMed: 25157647]
42. Golub SA, et al. From efficacy to effectiveness: facilitators and barriers to PrEP acceptability and motivations for adherence among MSM and transgender women in New York City. *AIDS Patient Care STDS.* 2013; 27(4):248–54. [PubMed: 23565928]
43. Baeten JM, et al. Preexposure prophylaxis for HIV prevention: where have we been and where are we going? *J Acquir Immune Defic Syndr.* 2013; 63(Suppl 2):S122–9. [PubMed: 23764623]
44. Ware NC, et al. What's love got to do with it? Explaining adherence to oral antiretroviral pre-exposure prophylaxis for HIV-serodiscordant couples. *J Acquir Immune Defic Syndr.* 2012; 59(5):463–8. [PubMed: 22267018]
45. Haberer JE, et al. Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa. *PLoS Med.* 2013; 10(9):e1001511. [PubMed: 24058300]
46. Corneli A, et al. Perception of HIV risk and adherence to a daily, investigational pill for HIV prevention in FEM-PrEP. *J Acquir Immune Defic Syndr.* 2014; 67(5):555–63. [PubMed: 25393942]
47. Corneli AL, et al. A descriptive analysis of perceptions of HIV risk and worry about acquiring HIV among FEM-PrEP participants who seroconverted in Bondo, Kenya, and Pretoria, South Africa. *J Int AIDS Soc.* 2014; 17(3 Suppl 2):19152. [PubMed: 25224613]

48. van der Straten A, et al. Perspectives on use of oral and vaginal antiretrovirals for HIV prevention: the VOICE-C qualitative study in Johannesburg, South Africa. *J Int AIDS Soc.* 2014; 17(3 Suppl 2):19146. [PubMed: 25224610]
49. MRC Clinical Trials Unit. PROUD study interim analysis finds pre-exposure prophylaxis (PrEP) is highly protective against HIV for gay men and other men who have sex with men in the UK. 2014. 10/16/14 1/25/15]; Available from: http://www.proud.mrc.ac.uk/pdf/PROUD_Statement_161014.pdf
50. Kirby T, Thornber-Dunwell M. Uptake of PrEP for HIV slow among MSM. *Lancet.* 2014; 383(9915):399–400. [PubMed: 24494225]
51. Flash C, et al. Two years of Truvada for pre-exposure prophylaxis utilization in the US. *J Int AIDS Soc.* 2014; 17(4 Suppl 3):19730. [PubMed: 25397476]
52. Cohen SE, et al. High Interest in Pre-exposure Prophylaxis Among Men Who Have Sex with Men at Risk for HIV-Infection: Baseline Data from the US PrEP Demonstration Project. *J Acquir Immune Defic Syndr.* 2014
53. Galindo GR, et al. Community member perspectives from transgender women and men who have sex with men on pre-exposure prophylaxis as an HIV prevention strategy: implications for implementation. *Implement Sci.* 2012; 7:116. [PubMed: 23181780]
54. Tellalian D, et al. Pre-Exposure Prophylaxis (PrEP) for HIV Infection: Results of a Survey of HIV Healthcare Providers Evaluating Their Knowledge, Attitudes, and Prescribing Practices. *AIDS Patient Care STDS.* 2013; 27(10):553–9. [PubMed: 24053478]
55. Tripathi A, et al. Preexposure prophylaxis for HIV infection: healthcare providers' knowledge, perception, and willingness to adopt future implementation in the southern US. *South Med J.* 2012; 105(4):199–206. [PubMed: 22475669]
56. White JM, et al. Evolution of Massachusetts physician attitudes, knowledge, and experience regarding the use of antiretrovirals for HIV prevention. *AIDS Patient Care STDS.* 2012; 26(7): 395–405. [PubMed: 22694239]
57. Clinician Consultation Center at UCSF. The CCC Pre-Exposure Prophylaxis Service. 1/25/15]; Available from: <http://nccc.ucsf.edu/clinical-resources/pep-resources/prep/>
58. Project Inform. PrEP/PEP Point-of-Care Cards. 1/25/15]; Available from: <http://www.projectinform.org/prep-pep-cards/>
59. Center, T.N.L.H.E.. [4/17/14 2014] Taking a History of Sexual Health: Opening the Door to Effective HIV and STI Prevention (webinar). Available from: <http://www.lgbthealtheducation.org/training/online-courses/neaetc2014/>
60. Johns Hopkins Institute for Clinical and Translational Research. HIV Pre-Exposure Prophylaxis (PrEP) Risk Assessment Tool: Individual Risk Calculator. 1/25/15]; Available from: <https://ictrweb.johnshopkins.edu/ictr/utility/prep.cfm>
61. Gilead Sciences Inc.. Truvada for a Pre-exposure Prophylaxis Indication: Risk Evaluation and Mitigation Strategy (REMS). 1/25/15]; Available from: <http://www.truvadapreprems.com/>
62. King HL, et al. Pre-exposure prophylaxis accessibility research and evaluation (PrEPARE Study). *AIDS Behav.* 2014; 18(9):1722–5. [PubMed: 25017425]
63. My PrEP Experience. Truvada Track - monitoring insurance and Medicaid coverage of Truvada for PrEP. 1/27/15]; Available from: <http://myprepexperience.blogspot.com/p/truvada-track.html>
64. Project Inform. How to choose a health plan in Covered California. 12/18/14; Available from: <http://www.projectinform.org/pdf/CCguide.pdf>.
65. Washington State Department of Health. Pre-Exposure Prophylaxis Drug Assistance Program (PrEP DAP). 1/27/15]; Available from: <http://www.doh.wa.gov/YouandYourFamily/IllnessandDisease/HIVAIDS/HIVCareClientServices/PrEPDAP>
66. Gilead Sciences Inc.. Truvada for PrEP Medication Assistance Program. 1/27/15]; Available from: http://www.gilead.com/responsibility/us-patient-access/truvada_for_prep_medication_assistance_program
67. Sionean C, et al. HIV Risk, Prevention, and Testing Behaviors Among Heterosexuals at Increased Risk for HIV Infection - National HIV Behavioral Surveillance System, 21 U.S. Cities, 2010. *MMWR Surveill Summ.* 2014; 63(Suppl 14):1–39. [PubMed: 25522191]

68. Finlayson TJ, et al. HIV risk, prevention, and testing behaviors among men who have sex with men--National HIV Behavioral Surveillance System, 21 U.S. cities, United States, 2008. *MMWR Surveill Summ.* 2011; 60(14):1–34. [PubMed: 22031280]
69. Broz D, et al. HIV infection and risk, prevention, and testing behaviors among injecting drug users -- National HIV Behavioral Surveillance System, 20 U.S. cities, 2009. *MMWR Surveill Summ.* 2014; 63(6):1–51. [PubMed: 24990587]
70. United States Presidential Commission on HIV/AIDS, National HIV/AIDS Strategy for the United States. White House Office of National AIDS Policy; 2010.
71. Un médicament pris au moment des rapports sexuels réduit efficacement le risque d'infection. 01/05/15]; Available from: <http://www.ipergay.fr/un-grand-succes-dans-la-lutte-contre-le-vih-sida.html>
72. Fonsart J, CC.; Spire, B.; Molina, J-M. High adherence rate to intermittent oral PrEP with TDF/FTC among high risk MSM (ANRS IPERGAY). 20th International AIDS Conference (AIDS 2014)2014; Melbourne.
73. Kibengo FM, et al. Safety, adherence and acceptability of intermittent tenofovir/emtricitabine as HIV pre-exposure prophylaxis (PrEP) among HIV-uninfected Ugandan volunteers living in HIV-serodiscordant relationships: a randomized, clinical trial. *PLoS One.* 2013; 8(9):e74314. [PubMed: 24086333]
74. Mutua G, et al. Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers. *PLoS One.* 2012; 7(4):e33103. [PubMed: 22511916]
75. Winner B, et al. Effectiveness of long-acting reversible contraception. *N Engl J Med.* 2012; 366(21):1998–2007. [PubMed: 22621627]
76. Eisingerich AB, et al. Attitudes and acceptance of oral and parenteral HIV preexposure prophylaxis among potential user groups: a multinational study. *PLoS One.* 2012; 7(1):e28238. [PubMed: 22247757]
77. Meyers K, et al. High Interest in a Long-Acting Injectable Formulation of Pre-Exposure Prophylaxis for HIV in Young Men Who Have Sex with Men in NYC: A P18 Cohort Substudy. *PLoS One.* 2014; 9(12):e114700. [PubMed: 25502768]
78. Wheelock A, et al. Are Thai MSM willing to take PrEP for HIV prevention? An analysis of attitudes, preferences and acceptance. *PLoS One.* 2013; 8(1):e54288. [PubMed: 23342121]
79. Andrews CD, et al. Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus. *Science.* 2014; 343(6175):1151–4. [PubMed: 24594934]
80. Study to Evaluate the Safety Tolerability and Acceptability of Long Acting Injections of the Human Immunodeficiency Virus (HIV) Integrase Inhibitor, GSK1265744, in HIV Uninfected Men (ECLAIR). 01/05/2015]; Available from: <https://http://www.clinicaltrials.gov/ct2/show/NCT02076178>
81. Spreen WR, Margolis DA, Pottage JC Jr. Long-acting injectable antiretrovirals for HIV treatment and prevention. *Curr Opin HIV AIDS.* 2013; 8(6):565–71. [PubMed: 24100877]
82. HPTN 076: Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278 LA, for Pre Exposure Prophylaxis (PrEP). 01/05/15]; Available from: http://www.hptn.org/research_studies/hptn076.asp
83. Devlin B, et al. Development of dapivirine vaginal ring for HIV prevention. *Antiviral Res.* 2013; 100(Suppl):S3–8. [PubMed: 24188702]
84. Boffito M, et al. New approaches to antiretroviral drug delivery: challenges and opportunities associated with the use of long-acting injectable agents. *Drugs.* 2014; 74(1):7–13. [PubMed: 24327298]

Table 1

Antiretroviral resistance among active-arm seroconverters in PrEP trials

PrEP Trial	Resistance in acutely infected pts at baseline (active arm)	Resistance during follow-up (active arm)
iPrEx [4, 22]	<ul style="list-style-type: none"> • 2/2 acutely infected pts with resistance: <ul style="list-style-type: none"> ○ 1 M184V (standard seq.) ○ 1 M184I (standard seq.) 	<ul style="list-style-type: none"> • No resistance detected by standard seq. among 48 active arm seroconverters • 2 pts with minor variant M184I <ul style="list-style-type: none"> ○ 1 detected by AS-PCR ○ 1 by 454 seq.
Partners PrEP [2, 23]	<ul style="list-style-type: none"> • 3/12 acutely infected pts with resistance <ul style="list-style-type: none"> ○ 1 K65R/K70E in TDF group (standard seq.) ○ 1 M184V in TDF/FTC group (standard seq.) ○ 1 M184V in TDF/FTC group (454 seq.) 	<ul style="list-style-type: none"> • No resistance detected by standard seq. in 51 active arm seroconverters • 4 pts with minor variant resistance <ul style="list-style-type: none"> ○ 3 in TDF/FTC arm: 2 M184V; 1 M184IV and K65R ○ 1 in TDF arm: M184I (unlikely selected by PrEP exposure)
TDF2 [5]	<ul style="list-style-type: none"> • 1/1 acutely infected ppt with resistance: K65R, M184V, and A62V (standard seq.) 	<ul style="list-style-type: none"> • No resistance reported in 9 active arm seroconverters using standard and ultrasensitive (Qiagen) sequencing
FemPrEP [24, 32]	<ul style="list-style-type: none"> • 3/6 pts with first evidence of infection at the first post-enrollment visit <ul style="list-style-type: none"> ○ 2 M184V ○ 1 M184I 	<ul style="list-style-type: none"> • No resistance detected by standard seq. in 27 active arm seroconverters • 1 seroconverters with minor variant resistance: M184I
BKK TDF study [3]	<ul style="list-style-type: none"> ○ No acutely infected pts in active arm 	<ul style="list-style-type: none"> ○ No TDF resistance (K65R, K70E) among 15 seroconverters in active arm

Standard seq.: Standard consensus sequencing; Ppt: participant; AS-PCR: allele-specific polymerase chain reaction; 454 seq: 454 deep sequencing